A groundbreaking new study published in the journal Neurology illuminates the shared genetic architecture underlying multiple sclerosis (MS) across diverse ancestries, including South Asian, African, and European populations. Conducted by researchers at Queen Mary University of London, this extensive analysis challenges the historical Eurocentric focus in MS genetic research and underscores the crucial role of inclusivity in unraveling the complex genetic basis of this debilitating autoimmune disorder.
Multiple sclerosis is an immune-mediated disease characterized by the demyelination of nerve fibers within the central nervous system, leading to a spectrum of neurological symptoms and long-term disability. Affecting over two million individuals worldwide—approximately 150,000 in the UK alone—MS presents varying clinical trajectories influenced by both genetic predispositions and environmental factors. Despite its global impact, most prior genetic investigations of MS risk have been limited to populations of European ancestry, potentially overlooking critical variants prevalent in other ethnic groups.
The investigative team leveraged genomic data from more than 3,000 MS patients alongside a control cohort exceeding 27,000 individuals without MS. Participants were drawn predominantly from the ADAMS Project, a UK-based initiative specifically designed to enhance ethnic diversity in MS research cohorts, alongside data from the expansive UK Biobank. This meta-analytic approach enabled the researchers to perform high-resolution genetic association analyses, focusing keenly on the major histocompatibility complex (MHC) region—a locus pivotal in immune function and previously implicated as a key contributor to MS susceptibility.
Intriguingly, the study found that MHC variants were strongly associated with MS risk not only in individuals of European descent but also in those of South Asian and African ancestry. This reinforces the notion that common immunogenetic pathways are central to MS pathology across populations. The immune mechanisms implicated by these variants suggest a conserved biological underpinning in the way the disease develops, regardless of ancestral background.
However, the analysis also revealed subtle but significant differences in genetic variant frequencies and effects among ancestries. Notably, the researchers identified a protective genetic variant that is relatively frequent in South Asian populations yet rare in Europeans. Such ancestry-specific variants likely elude detection in genetic studies confined to homogeneous European cohorts, underscoring an intrinsic bias in previous research methodologies. This novel finding reveals the complex interplay of diverse genetic factors that modulate susceptibility and resistance to MS within different ethnic groups.
Crucially, the study demonstrated that while many MS-associated variants discovered in European populations are also present in South Asian and African groups, the magnitude and direction of their effects vary. This observation suggests that although the overarching disease mechanisms may be shared, the precise genetic architecture—and, by extension, risk prediction models—may require tailoring to individual ancestries for accurate clinical applicability. This nuance has profound implications for advancing personalized medicine in MS.
Beyond genetics, MS disparities manifest clearly in disease outcomes. Prior epidemiological studies have shown that individuals from Black ethnic backgrounds frequently experience a more aggressive disease course, with increased disability and poorer prognoses compared to their White counterparts. The present study acknowledges that genetic differences alone cannot fully account for these disparities, emphasizing the importance of social determinants of health, healthcare access, and potential biases in diagnosis and treatment.
One consequence of the longstanding underrepresentation of diverse populations in MS genetics is the potential for misdiagnosis or delayed diagnosis among minority groups. This gap not only affects patient care but also limits the reliability of genetic risk profiling tools developed predominantly from European data. Consequently, predictive models and therapeutic interventions may perform inadequately in non-European populations, perpetuating health inequities.
The empowerment of diverse participant inclusion in research—exemplified by the ADAMS Project—aims to rectify these historical limitations. By broadening the scope of genetic inquiry, researchers can unmask previously obscured risk factors, refine disease understanding, and build more equitable prediction algorithms. As Dr. Benjamin Jacobs, clinical lecturer and co-author, articulates, expanding ancestral representation enables the discovery of critical insights that remain hidden in monolithic datasets.
Dr. Ruth Dobson, the study’s lead investigator and Professor of Clinical Neurology, highlights the dual imperative of fairness and scientific integrity underpinning this research. She stresses that excluding vast segments of the global population from genetic studies impedes comprehensive knowledge acquisition and innovation. Inclusive research fosters both ethical responsibility and superior scientific outcomes.
The MS Society, represented by Senior Research Communications Manager Caitlin Astbury, echoes the necessity of diversity in research participation. They emphasize that MS affects individuals across all ethnicities and backgrounds, demanding that genetic and clinical studies reflect this reality to ensure balanced progress in treatment, diagnosis, and risk assessment advancements.
This study’s findings propel the MS research field toward more holistic and representative genetic explorations, paving the way for tailored therapeutic strategies. It simultaneously serves as a clarion call to dismantle the Eurocentric bias that has historically constrained our understanding of complex diseases. Enhanced genetic diversity in research cohorts promises to yield a more nuanced appreciation of MS pathogenesis and improve health equity globally.
In summary, Queen Mary University of London’s team provides compelling evidence that multiple sclerosis shares foundational genetic determinants across diverse ancestries, while also revealing population-specific variants that can profoundly influence risk and clinical application. The study advocates for an urgent transformation in genetic research paradigms, prioritizing inclusivity to optimize patient outcomes and elevate scientific rigor.
Subject of Research: People
Article Title: Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds
News Publication Date: 6-Mar-2026
Web References:
- ADAMS Project: https://app.mantal.co.uk/adams
- Related BMJ Open Study: https://bmjopen.bmj.com/content/13/5/e071656
References:
Jacobs, B., et al., “Genetic determinants of Multiple Sclerosis susceptibility in people from diverse ancestral backgrounds,” Neurology, DOI: 10.1212/WNL.0000000000214708
Keywords: multiple sclerosis, genes, diversity, ethnicity, ancestry, immune disorders, genetic analysis, medical genetics, genomics
